MAM
AMG plans media blitz for Oliver Sean’s debut album
MUMBAI: Singer-cum-song writer Oliver Sean, who is exclusively managed by AMG india , an artiste management company, has signed a deal with Times Music to release his debut English album.
A press release says that the debut album titled I like it would now be available in India and world-wide through the prestigious Times music distribution network and their various international licensees abroad. Cassettes and CDs of this album will hit music stores on 25 September 03.
The release also states that the video of the title track I Like it will also be aired across all major music channel around this time. Throughout the month of October, Oliver will extensively be seen across various music channels like MTV, Channel [V], B4U, Zee Music amongst others; and will be interviewed by various news channel such as NDTV, Star News and Zee News. Sean will also be heard on radio stations across the country, with his songs and interviews featuring extensively.
To promote the album across India, Seam will be on whirlwind tour across Mumbai, Pune, Hyderabad, Bangalore, Chennai, Delhi, Chandigarh, Jaipur, Kolkata, besides others. The promotional tour will involve live concerts, press conferences, autograph signing sessions amongst others.
Besides, the release says that AMG is planning a major media blitz to promote this musical talent, with his poster boy image being splashed across all major newspapers and magazines across India.
According to a release, the album is a true-expression of this highly talented guitarist and his cool, honest, beautiful music. This album encapsulates his musical influences of classic rock, the fusion element of the orient and the melancholic beauty of blues. Sean claims to have evolved his own sound – but with an air of authenticity that unites the many elements. Sean has tried to revitalise the fusion element which can be felt in his title track I Like it (a classic rock song with an unique blend of tablas with the acoustic guitar); Tonite (a blues rock song with a cool acoustic guitar twist); Nicole – with a unique fusion element on a predominantly country style song.
Incidentally, the release claims that Sean is the only International artiste (of Italian and Portuguese-Goan descent) with Indian roots to have been invited to perform not once but twice at the prestigious Mick Jagger Centre in UK. This, claims the release, bears testimony to his artistic talent as well as to his grit and determination.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
